<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName archivearticle3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Arthritis Rheumatol</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)2326-5205</journal-id><journal-id journal-id-type="publisher-id">ART</journal-id><journal-title-group><journal-title>Arthritis &amp; Rheumatology (Hoboken, N.j.)</journal-title></journal-title-group><issn pub-type="ppub">2326-5191</issn><issn pub-type="epub">2326-5205</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6032847</article-id><article-id pub-id-type="doi">10.1002/art.40466</article-id><article-id pub-id-type="publisher-id">ART40466</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Pediatric Rheumatology</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Subcutaneous Abatacept in Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis </plain></SENT>
</text></SecTag></article-title><subtitle>Results From a Phase <styled-content style="fixed-case">III</styled-content> Open‐Label Study</subtitle><alt-title alt-title-type="left-running-head">Brunner et al</alt-title></title-group><contrib-group><contrib id="art40466-cr-0001" contrib-type="author" corresp="yes"><name><surname>Brunner</surname><given-names>Hermine I.</given-names></name><degrees>MD, MSc, MBA</degrees><address><email>hermine.brunner@cchmc.org</email></address><xref ref-type="aff" rid="art40466-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="art40466-cr-0002" contrib-type="author"><name><surname>Tzaribachev</surname><given-names>Nikolay</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="art40466-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="art40466-cr-0003" contrib-type="author"><name><surname>Vega‐Cornejo</surname><given-names>Gabriel</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="art40466-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="art40466-cr-0004" contrib-type="author"><name><surname>Louw</surname><given-names>Ingrid</given-names></name><degrees>MMED, MBChB</degrees><xref ref-type="aff" rid="art40466-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="art40466-cr-0005" contrib-type="author"><name><surname>Berman</surname><given-names>Alberto</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="art40466-aff-0005">
<sup>5</sup>
</xref></contrib><contrib id="art40466-cr-0006" contrib-type="author"><name><surname>Calvo Penadés</surname><given-names>Inmaculada</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="art40466-aff-0006">
<sup>6</sup>
</xref></contrib><contrib id="art40466-cr-0007" contrib-type="author"><name><surname>Antón</surname><given-names>Jordi</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="art40466-aff-0007">
<sup>7</sup>
</xref></contrib><contrib id="art40466-cr-0008" contrib-type="author"><name><surname>Ávila‐Zapata</surname><given-names>Francisco</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="art40466-aff-0008">
<sup>8</sup>
</xref></contrib><contrib id="art40466-cr-0009" contrib-type="author"><name><surname>Cuttica</surname><given-names>Rubén</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="art40466-aff-0009">
<sup>9</sup>
</xref></contrib><contrib id="art40466-cr-0010" contrib-type="author"><name><surname>Horneff</surname><given-names>Gerd</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="art40466-aff-0010">
<sup>10</sup>
</xref></contrib><contrib id="art40466-cr-0011" contrib-type="author"><name><surname>Foeldvari</surname><given-names>Ivan</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="art40466-aff-0011">
<sup>11</sup>
</xref></contrib><contrib id="art40466-cr-0012" contrib-type="author"><name><surname>Keltsev</surname><given-names>Vladimir</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="art40466-aff-0012">
<sup>12</sup>
</xref></contrib><contrib id="art40466-cr-0013" contrib-type="author"><name><surname>Kingsbury</surname><given-names>Daniel J.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="art40466-aff-0013">
<sup>13</sup>
</xref></contrib><contrib id="art40466-cr-0014" contrib-type="author"><name><surname>Viola</surname><given-names>Diego Oscar</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="art40466-aff-0014">
<sup>14</sup>
</xref></contrib><contrib id="art40466-cr-0015" contrib-type="author"><name><surname>Joos</surname><given-names>Rik</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="art40466-aff-0015">
<sup>15</sup>
</xref></contrib><contrib id="art40466-cr-0016" contrib-type="author"><name><surname>Lauwerys</surname><given-names>Bernard</given-names></name><degrees>PhB, MBChB, PhD, MD</degrees><xref ref-type="aff" rid="art40466-aff-0016">
<sup>16</sup>
</xref></contrib><contrib id="art40466-cr-0017" contrib-type="author"><name><surname>Paz Gastañaga</surname><given-names>Maria Eliana</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="art40466-aff-0017">
<sup>17</sup>
</xref></contrib><contrib id="art40466-cr-0018" contrib-type="author"><name><surname>Rama</surname><given-names>Maria Elena</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="art40466-aff-0018">
<sup>18</sup>
</xref></contrib><contrib id="art40466-cr-0019" contrib-type="author"><name><surname>Wouters</surname><given-names>Carine</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="art40466-aff-0019">
<sup>19</sup>
</xref></contrib><contrib id="art40466-cr-0020" contrib-type="author"><name><surname>Bohnsack</surname><given-names>John</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="art40466-aff-0020">
<sup>20</sup>
</xref></contrib><contrib id="art40466-cr-0021" contrib-type="author"><name><surname>Breedt</surname><given-names>Johannes</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="art40466-aff-0021">
<sup>21</sup>
</xref></contrib><contrib id="art40466-cr-0022" contrib-type="author"><name><surname>Fischbach</surname><given-names>Michel</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="art40466-aff-0022">
<sup>22</sup>
</xref></contrib><contrib id="art40466-cr-0023" contrib-type="author"><name><surname>Lutz</surname><given-names>Thomas</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="art40466-aff-0023">
<sup>23</sup>
</xref></contrib><contrib id="art40466-cr-0024" contrib-type="author"><name><surname>Minden</surname><given-names>Kirsten</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="art40466-aff-0024">
<sup>24</sup>
</xref></contrib><contrib id="art40466-cr-0025" contrib-type="author"><name><surname>Miraval</surname><given-names>Tatiana</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="art40466-aff-0025">
<sup>25</sup>
</xref></contrib><contrib id="art40466-cr-0026" contrib-type="author"><name><surname>Ally</surname><given-names>Mahmood M. T. M.</given-names></name><degrees>MBChB</degrees><xref ref-type="aff" rid="art40466-aff-0026">
<sup>26</sup>
</xref></contrib><contrib id="art40466-cr-0027" contrib-type="author"><name><surname>Rubio‐Pérez</surname><given-names>Nadina</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="art40466-aff-0027">
<sup>27</sup>
</xref></contrib><contrib id="art40466-cr-0028" contrib-type="author"><name><surname>Solau Gervais</surname><given-names>Elisabeth</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="art40466-aff-0028">
<sup>28</sup>
</xref></contrib><contrib id="art40466-cr-0029" contrib-type="author"><name><surname>van Zyl</surname><given-names>Riana</given-names></name><degrees>MBChB</degrees><xref ref-type="aff" rid="art40466-aff-0029">
<sup>29</sup>
</xref></contrib><contrib id="art40466-cr-0030" contrib-type="author"><name><surname>Li</surname><given-names>Xiaohui</given-names></name><degrees>BSc</degrees><xref ref-type="aff" rid="art40466-aff-0030">
<sup>30</sup>
</xref></contrib><contrib id="art40466-cr-0031" contrib-type="author"><name><surname>Nys</surname><given-names>Marleen</given-names></name><degrees>MSc</degrees><xref ref-type="aff" rid="art40466-aff-0031">
<sup>31</sup>
</xref></contrib><contrib id="art40466-cr-0032" contrib-type="author"><name><surname>Wong</surname><given-names>Robert</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="art40466-aff-0030">
<sup>30</sup>
</xref></contrib><contrib id="art40466-cr-0033" contrib-type="author"><name><surname>Banerjee</surname><given-names>Subhashis</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="art40466-aff-0030">
<sup>30</sup>
</xref></contrib><contrib id="art40466-cr-0034" contrib-type="author"><name><surname>Lovell</surname><given-names>Daniel J.</given-names></name><degrees>MD, MPH</degrees><xref ref-type="aff" rid="art40466-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="art40466-cr-0035" contrib-type="author"><name><surname>Martini</surname><given-names>Alberto</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="art40466-aff-0032">
<sup>32</sup>
</xref></contrib><contrib id="art40466-cr-0036" contrib-type="author"><name><surname>Ruperto</surname><given-names>Nicolino</given-names></name><degrees>MD, MPH</degrees><xref ref-type="aff" rid="art40466-aff-0032">
<sup>32</sup>
</xref></contrib><contrib id="art40466-cr-0037" contrib-type="author"><collab collab-type="authors">the Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG)<contrib-group><contrib id="art40466-cr-0038" contrib-type="author"><name><surname>Becker</surname><given-names>Mara L</given-names></name><xref ref-type="contrib" rid="art40466-cr-0037"/></contrib><contrib id="art40466-cr-0039" contrib-type="author"><name><surname>Ilowite</surname><given-names>Norman T</given-names></name><xref ref-type="contrib" rid="art40466-cr-0037"/></contrib><contrib id="art40466-cr-0040" contrib-type="author"><name><surname>Dare</surname><given-names>Jason A</given-names></name><xref ref-type="contrib" rid="art40466-cr-0037"/></contrib><contrib id="art40466-cr-0041" contrib-type="author"><name><surname>Morris</surname><given-names>Paula K</given-names></name><xref ref-type="contrib" rid="art40466-cr-0037"/></contrib><contrib id="art40466-cr-0042" contrib-type="author"><name><surname>Beukelman</surname><given-names>Timothy G</given-names></name><xref ref-type="contrib" rid="art40466-cr-0037"/></contrib><contrib id="art40466-cr-0043" contrib-type="author"><name><surname>Wagner‐Weiner</surname><given-names>Linda</given-names></name><xref ref-type="contrib" rid="art40466-cr-0037"/></contrib><contrib id="art40466-cr-0044" contrib-type="author"><name><surname>Zemel</surname><given-names>Lawrence</given-names></name><xref ref-type="contrib" rid="art40466-cr-0037"/></contrib><contrib id="art40466-cr-0045" contrib-type="author"><name><surname>Quartier</surname><given-names>Pierre</given-names></name><xref ref-type="contrib" rid="art40466-cr-0037"/></contrib><contrib id="art40466-cr-0046" contrib-type="author"><name><surname>Kone‐Paut</surname><given-names>Isabelle</given-names></name><xref ref-type="contrib" rid="art40466-cr-0037"/></contrib><contrib id="art40466-cr-0047" contrib-type="author"><name><surname>Belot</surname><given-names>Alexandre</given-names></name><xref ref-type="contrib" rid="art40466-cr-0037"/></contrib><contrib id="art40466-cr-0048" contrib-type="author"><name><surname>Gerloni</surname><given-names>Valeria</given-names></name><xref ref-type="contrib" rid="art40466-cr-0037"/></contrib><contrib id="art40466-cr-0049" contrib-type="author"><name><surname>Ferrandiz</surname><given-names>Manuel</given-names></name><xref ref-type="contrib" rid="art40466-cr-0037"/></contrib><contrib id="art40466-cr-0050" contrib-type="author"><name><surname>Van Rensburg</surname><given-names>Dina Janse</given-names></name><xref ref-type="contrib" rid="art40466-cr-0037"/></contrib><contrib id="art40466-cr-0051" contrib-type="author"><name><surname>Scheibel</surname><given-names>Iloite Maria</given-names></name><xref ref-type="contrib" rid="art40466-cr-0037"/></contrib><contrib id="art40466-cr-0052" contrib-type="author"><name><surname>Goldstein‐Schainberg</surname><given-names>Claudia</given-names></name><xref ref-type="contrib" rid="art40466-cr-0037"/></contrib><contrib id="art40466-cr-0053" contrib-type="author"><name><surname>Silva</surname><given-names>Clovis</given-names></name><xref ref-type="contrib" rid="art40466-cr-0037"/></contrib><contrib id="art40466-cr-0054" contrib-type="author"><name><surname>Terreri</surname><given-names>Maria Teresa Sande e Lemos Ascensao</given-names></name><xref ref-type="contrib" rid="art40466-cr-0037"/></contrib><contrib id="art40466-cr-0055" contrib-type="author"><name><surname>Gamir</surname><given-names>Maria</given-names></name><xref ref-type="contrib" rid="art40466-cr-0037"/></contrib><contrib id="art40466-cr-0056" contrib-type="author"><name><surname>Burgos Vargas</surname><given-names>Ruben</given-names></name><xref ref-type="contrib" rid="art40466-cr-0037"/></contrib><contrib id="art40466-cr-0057" contrib-type="author"><name><surname>Faugier Fuentes</surname><given-names>Enrique</given-names></name><xref ref-type="contrib" rid="art40466-cr-0037"/></contrib><contrib id="art40466-cr-0058" contrib-type="author"><name><surname>Cimaz</surname><given-names>Rolando</given-names></name><xref ref-type="contrib" rid="art40466-cr-0037"/></contrib><contrib id="art40466-cr-0059" contrib-type="author"><name><surname>Alessio</surname><given-names>Maria</given-names></name><xref ref-type="contrib" rid="art40466-cr-0037"/></contrib><contrib id="art40466-cr-0060" contrib-type="author"><name><surname>Espada</surname><given-names>Graciela</given-names></name><xref ref-type="contrib" rid="art40466-cr-0037"/></contrib></contrib-group></collab></contrib></contrib-group><aff id="art40466-aff-0001">
<label><sup>1</sup></label>
<institution>Cincinnati Children's Hospital Medical Center</institution>
<named-content content-type="city">Cincinnati</named-content>
<named-content content-type="country-part">Ohio</named-content>
</aff><aff id="art40466-aff-0002">
<label><sup>2</sup></label>
<institution>Pediatric Rheumatology Research Institute</institution>
<named-content content-type="city">Bad Bramstedt</named-content>
<country country="DE">Germany</country>
</aff><aff id="art40466-aff-0003">
<label><sup>3</sup></label>
<institution>Hospital México Americano</institution>
<named-content content-type="city">Guadalajara</named-content>
<country country="MX">Mexico</country>
</aff><aff id="art40466-aff-0004">
<label><sup>4</sup></label>
<institution>Panorama Medical Centre</institution>
<named-content content-type="city">Cape Town</named-content>
<country country="ZA">South Africa</country>
</aff><aff id="art40466-aff-0005">
<label><sup>5</sup></label>
<institution>Hospital Angel C. Padilla</institution>
<named-content content-type="city">Tucumán</named-content>
<country country="AR">Argentina</country>
</aff><aff id="art40466-aff-0006">
<label><sup>6</sup></label>
<institution>Hospital Universitario y Politécnico de La Fe</institution>
<named-content content-type="city">Valencia</named-content>
<country country="ES">Spain</country>
</aff><aff id="art40466-aff-0007">
<label><sup>7</sup></label>
<institution>Hospital Sant Joan de Déu</institution>
<named-content content-type="city">Barcelona</named-content>
<country country="ES">Spain</country>
</aff><aff id="art40466-aff-0008">
<label><sup>8</sup></label>
<institution>Hospital Star Medica</institution>
<named-content content-type="city">Merida</named-content>
<country country="MX">Mexico</country>
</aff><aff id="art40466-aff-0009">
<label><sup>9</sup></label>
<institution>Hospital General de Niños Pedro de Elizalde</institution>
<named-content content-type="city">Buenos Aires</named-content>
<country country="AR">Argentina</country>
</aff><aff id="art40466-aff-0010">
<label><sup>10</sup></label>
<institution>Asklepios Clinic Sankt Augustin</institution>
<named-content content-type="city">Sankt Augustin</named-content>
<country country="DE">Germany</country>
</aff><aff id="art40466-aff-0011">
<label><sup>11</sup></label>
<institution>Hamburg Centre for Pediatric and Adolescent Rheumatology</institution>
<named-content content-type="city">Hamburg</named-content>
<country country="DE">Germany</country>
</aff><aff id="art40466-aff-0012">
<label><sup>12</sup></label>
<institution>Togliatti City Clinical Hospital No.5</institution>
<named-content content-type="city">Togliatti</named-content>
<country>Russia</country>
</aff><aff id="art40466-aff-0013">
<label><sup>13</sup></label>
<institution>Randall Children's Hospital at Legacy Emanuel</institution>
<named-content content-type="city">Portland</named-content>
<named-content content-type="country-part">Oregon</named-content>
</aff><aff id="art40466-aff-0014">
<label><sup>14</sup></label>
<institution>CAICI Institute</institution>
<named-content content-type="city">Rosario City</named-content>
<country country="AR">Argentina</country>
</aff><aff id="art40466-aff-0015">
<label><sup>15</sup></label>
<institution>Universitair Ziekenhuis Gent</institution>
<named-content content-type="city">Ghent</named-content>
<country country="BE">Belgium</country>
</aff><aff id="art40466-aff-0016">
<label><sup>16</sup></label>
<institution>Université catholique de Louvain</institution>
<named-content content-type="city">Brussels</named-content>
<country country="BE">Belgium</country>
</aff><aff id="art40466-aff-0017">
<label><sup>17</sup></label>
<institution>Clínica Anglo Americana</institution>
<named-content content-type="city">Lima</named-content>
<country country="PE">Peru</country>
</aff><aff id="art40466-aff-0018">
<label><sup>18</sup></label>
<institution>Hospital de Niños de la Santísima Trinidad</institution>
<named-content content-type="city">Córdoba</named-content>
<country country="AR">Argentina</country>
</aff><aff id="art40466-aff-0019">
<label><sup>19</sup></label>
<institution>University Hospital Gasthuisberg</institution>
<named-content content-type="city">Leuven</named-content>
<country country="BE">Belgium</country>
</aff><aff id="art40466-aff-0020">
<label><sup>20</sup></label>
<institution>University of Utah School of Medicine</institution>
<named-content content-type="city">Salt Lake City</named-content>
</aff><aff id="art40466-aff-0021">
<label><sup>21</sup></label>
<institution>Steve Biko Academic Hospital, University of Pretoria</institution>
<named-content content-type="city">Pretoria</named-content>
<country country="ZA">South Africa</country>
</aff><aff id="art40466-aff-0022">
<label><sup>22</sup></label>
<institution>Pédiatrie 1, CHU Hautepierre</institution>
<named-content content-type="city">Strasbourg</named-content>
<country country="FR">France</country>
</aff><aff id="art40466-aff-0023">
<label><sup>23</sup></label>
<institution>University Hospital</institution>
<named-content content-type="city">Heidelberg</named-content>
<country country="DE">Germany</country>
</aff><aff id="art40466-aff-0024">
<label><sup>24</sup></label>
<institution>German Rheumatism Research Center and Charité University Medicine</institution>
<named-content content-type="city">Berlin</named-content>
<country country="DE">Germany</country>
</aff><aff id="art40466-aff-0025">
<label><sup>25</sup></label>
<institution>Hospital Nacional Edgardo Rebagliati Martins</institution>
<named-content content-type="city">Lima</named-content>
<country country="PE">Peru</country>
</aff><aff id="art40466-aff-0026">
<label><sup>26</sup></label>
<institution>University of Pretoria</institution>
<named-content content-type="city">Pretoria</named-content>
<country country="ZA">South Africa</country>
</aff><aff id="art40466-aff-0027">
<label><sup>27</sup></label>
<institution>Universidad Autónoma de Nuevo León, Hospital Universitario Dr. J. E. González</institution>
<named-content content-type="city">Monterrey</named-content>
<country country="MX">Mexico</country>
</aff><aff id="art40466-aff-0028">
<label><sup>28</sup></label>
<institution>CHU de Poitiers, Rheumatology</institution>
<named-content content-type="city">Poitiers</named-content>
<country country="FR">France</country>
</aff><aff id="art40466-aff-0029">
<label><sup>29</sup></label>
<institution>University of the Free State</institution>
<named-content content-type="city">Bloemfontein</named-content>
<country country="ZA">South Africa</country>
</aff><aff id="art40466-aff-0030">
<label><sup>30</sup></label>
<institution>Bristol‐Myers Squibb</institution>
<named-content content-type="city">Princeton</named-content>
<named-content content-type="country-part">New Jersey</named-content>
</aff><aff id="art40466-aff-0031">
<label><sup>31</sup></label>
<institution>Bristol‐Myers Squibb</institution>
<named-content content-type="city">Braine‐L'Alleud</named-content>
<country country="BE">Belgium</country>
</aff><aff id="art40466-aff-0032">
<label><sup>32</sup></label>
<institution>Istituto Giannina Gaslini</institution>
<named-content content-type="city">Genoa</named-content>
<country country="IT">Italy</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label>Address correspondence to Hermine I. Brunner, MD, MSc, MBA, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229. E‐mail. <email>hermine.brunner@cchmc.org</email>.</corresp></author-notes><pub-date pub-type="epub"><day>20</day><month>5</month><year>2018</year></pub-date><pub-date pub-type="ppub"><month>7</month><year>2018</year></pub-date><volume>70</volume><issue>7</issue><issue-id pub-id-type="doi">10.1002/art.v70.7</issue-id><fpage>1144</fpage><lpage>1154</lpage><history><date date-type="received"><day>06</day><month>10</month><year>2017</year></date><date date-type="accepted"><day>20</day><month>2</month><year>2018</year></date></history><permissions><copyright-statement content-type="article-copyright">© 2018 Bristol‐Myers Squibb. <italic>Arthritis &amp; Rheumatology</italic> published by Wiley Periodicals, Inc. on behalf of American College of Rheumatology. </copyright-statement><license license-type="creativeCommonsBy-nc"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:ART-70-1144.pdf"/><abstract id="art40466-abs-0001"><sec id="art40466-sec-0001"><title><text><SENT sid="1" pm="."><plain>Objective </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="2" pm="."><plain>To investigate the pharmacokinetics, effectiveness, and safety of subcutaneous (SC) abatacept treatment over 24 months in patients with polyarticular‐course juvenile idiopathic arthritis (JIA). </plain></SENT>
</text></SecTag></p></sec><sec id="art40466-sec-0002"><title><text><SENT sid="3" pm="."><plain>Methods </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="4" pm="."><plain>In this phase III, open‐label, international, multicenter, single‐arm study, patients with polyarticular JIA (cohort 1, ages 6–17 years and cohort 2, ages 2–5 years) in whom treatment with ≥1 disease‐modifying antirheumatic drug was unsuccessful received weight‐tiered SC abatacept weekly: 10 to &lt;25 kg (50 mg), 25 to &lt;50 kg (87.5 mg), ≥50 kg (125 mg). </plain></SENT>
<SENT sid="5" pm="."><plain>Patients who had met the JIA–American College of Rheumatology 30% improvement criteria (achieved a JIA‐ACR 30 response) at month 4 were given the option to continue SC abatacept to month 24. </plain></SENT>
<SENT sid="6" pm="."><plain>The primary end point was the abatacept steady‐state serum trough concentration (Cminss) in cohort 1 at month 4. </plain></SENT>
<SENT sid="7" pm="."><plain>Other outcome measures included JIA‐ACR 30, 50, 70, 90, 100, and inactive disease status, the median Juvenile Arthritis Disease Activity Score in 71 joints using the C‐reactive protein level (JADAS‐71–CRP) over time, safety, and immunogenicity. </plain></SENT>
</text></SecTag></p></sec><sec id="art40466-sec-0003"><title><text><SENT sid="8" pm="."><plain>Results </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="9" pm="."><plain>The median abatacept Cminss at month 4 (primary end point) and at month 24 was above the target therapeutic exposure (10 μg/ml) in both cohorts. </plain></SENT>
<SENT sid="10" pm="."><plain>The percentage of patients who had achieved JIA‐ACR 30, 50, 70, 90, or 100 responses or had inactive disease responses at month 4 (intent‐to‐treat population) was 83.2%, 72.8%, 52.6%, 28.3%, 14.5%, and 30.1%, respectively, in cohort 1 (n = 173) and 89.1%, 84.8%, 73.9%, 58.7%, 41.3%, and 50.0%, respectively, in cohort 2 (n = 46); the responses were maintained to month 24. </plain></SENT>
<SENT sid="11" pm="."><plain>The median (interquartile range) JADAS‐71–CRP improved from baseline to month 4: cohort 1, from 21.0 (13.5, 30.3) to 4.6 (2.1, 9.4); cohort 2, from 18.1 (14.0, 23.1) to 2.1 (0.3, 4.4). </plain></SENT>
<SENT sid="12" pm="."><plain>Improvements were sustained to month 24, at which time 27 of 173 patients (cohort 1) and 11 of 22 patients (cohort 2) had achieved JADAS‐71–CRP remission. </plain></SENT>
<SENT sid="13" pm="."><plain>No unexpected adverse events were reported; 4 of 172 patients (2.3%) in cohort 1 and 4 of 46 (8.7%) in cohort 2 developed anti‐abatacept antibodies, with no clinical effects. </plain></SENT>
</text></SecTag></p></sec><sec id="art40466-sec-0004"><title><text><SENT sid="14" pm="."><plain>Conclusion </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="15" pm="."><plain>Weight‐stratified SC abatacept yielded target therapeutic exposures across age and weight groups, was well tolerated, and improved polyarticular JIA symptoms over 24 months. </plain></SENT>
</text></SecTag></p></sec></abstract><funding-group><award-group><funding-source>Bristol‐Myers Squibb</funding-source></award-group></funding-group><counts><fig-count count="4"/><table-count count="2"/><page-count count="11"/><word-count count="8090"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>art40466</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>July 2018</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:version=5.4.3 mode:remove_FC converted:05.07.2018</meta-value></custom-meta></custom-meta-group></article-meta><notes><fn-group id="art40466-ntgp-0001"><fn id="art40466-note-1001"><p><text><SENT sid="16" pm="."><plain>ClinicalTrials.gov identifier: NCT01844518. </plain></SENT>
</text></p></fn><fn id="art40466-note-1002"><p><text><SENT sid="17" pm="."><plain>Supported by Bristol‐Myers Squibb. </plain></SENT>
</text></p></fn><fn id="art40466-note-1004"><p><text><SENT sid="18" pm="."><plain>Dr. Brunner has received consulting fees and/or speaking fees from AstraZeneca, Bristol‐Myers Squibb, Genentech, Janssen, Novartis, Pfizer, Sanofi, and Takeda (more than $10,000 each). </plain></SENT>
<SENT sid="19" pm="."><plain>Dr. Calvo Penadés has received speaking fees from AbbVie, Roche, Novartis, and Sobi (less than $10,000 each) and research support from Novartis. </plain></SENT>
<SENT sid="20" pm="."><plain>Dr. Antón has received speaking fees from AbbVie, Novartis, Pfizer, Roche, and Sobi (less than $10,000 each) and research support from Novartis and Pfizer. </plain></SENT>
<SENT sid="21" pm="."><plain>Dr. Horneff has received speaking fees from AbbVie, Pfizer, Chugai, Roche, and Novartis (less than $10,000 each). </plain></SENT>
<SENT sid="22" pm="."><plain>Dr. Lauwerys has received consulting fees from Bristol‐Myers Squibb, Servier, and Pfizer (less than $10,000 each) and research support from UCB, Janssen, and Pfizer. </plain></SENT>
<SENT sid="23" pm="."><plain>Dr. Paz Gastañaga has received research support from Pfizer, Novartis, Sanofi, and GlaxoSmithKline. </plain></SENT>
<SENT sid="24" pm="."><plain>Dr. Minden has received speaking fees and/or honoraria from AbbVie, Pfizer, Roche, and Pharm‐Allergan (more than $10,000 each) and research support from AbbVie, Pfizer, and Roche. </plain></SENT>
<SENT sid="25" pm="."><plain>Dr. Solau Gervais has received speaking fees from Bristol‐Myers Squibb, Pfizer, Roche, AbbVie, Novartis, and MSD (less than $10,000 each). </plain></SENT>
<SENT sid="26" pm="."><plain>Ms Li, Ms Nys, and Drs. </plain></SENT>
<SENT sid="27" pm="."><plain>Wong and Banerjee own stock or stock options in Bristol‐Myers Squibb. </plain></SENT>
<SENT sid="28" pm="."><plain>Dr. Lovell has received consulting fees and/or speaking fees from AbbVie, Boehringer Ingelheim, Bristol‐Myers Squibb, Celgene, Genentech, GlaxoSmithKline, Janssen, Johnson &amp; Johnson, Novartis, Takeda, and UCB (more than $10,000 each) and research support from AbbVie, Bristol‐Myers Squibb, Pfizer, and Roche. </plain></SENT>
<SENT sid="29" pm="."><plain>Dr. Ruperto has received consulting fees and/or speaking fees from AbbVie, Ablynx, Amgen, AstraZeneca, Baxalta Biosimilars, Biogen Idec, Boehringer Ingelheim, Bristol‐Myers Squibb, Celgene, Eli Lilly and Company, EMD Serono, Gilead Sciences, Janssen, MedImmune, Novartis, Pfizer, R‐Pharm, Roche, Sanofi, Servier, and Takeda (more than $10,000 each). </plain></SENT>
</text></p></fn></fn-group></notes></front><body><p><text><SENT sid="30" pm="."><plain>Juvenile idiopathic arthritis (JIA) is a rheumatic disease presenting in children &lt;16 years of age 1, 2, 3. </plain></SENT>
<SENT sid="31" pm="."><plain>For polyarticular‐course JIA (JIA of any category with ≥5 affected joints 1, 4, 5), methotrexate (MTX) is the recommended first‐line disease‐modifying antirheumatic drug (DMARD) therapy 3. </plain></SENT>
<SENT sid="32" pm="."><plain>If disease activity remains moderate or high after 3 months of MTX treatment, a biologic agent is frequently initiated and a tumor necrosis factor inhibitor (TNFi) is most commonly employed, followed by an anti–interleukin‐6 agent or abatacept 6. </plain></SENT>
<SENT sid="33" pm="."><plain>However, it is important to have multiple treatment options in this pediatric population, particularly for patients who are intolerant of or do not respond to MTX or TNFi 2, 7, 8, 9, 10, 11, 12, 13, 14, 15 or who live in a tuberculosis‐endemic country. </plain></SENT>
</text></p><p><text><SENT sid="34" pm="."><plain>Abatacept, which selectively modulates the CD80/CD86:CD28 costimulatory signal required for full T cell activation, has a distinct mechanism of action upstream of that of other currently available treatments for rheumatic diseases 13, 16, 17, 18. </plain></SENT>
<SENT sid="35" pm="."><plain>In adults with rheumatoid arthritis (RA), intravenous (IV) abatacept inhibits structural damage, reduces disease progression, and improves function and health‐related quality of life, with good safety and tolerability 16, 19, 20. </plain></SENT>
<SENT sid="36" pm="."><plain>IV‐administered abatacept has been proven effective and well tolerated in polyarticular JIA clinical trials and real‐world settings 21, with benefits of treatment sustained up to 7 years in patients ages 6–17 years 2, 9, 13. </plain></SENT>
<SENT sid="37" pm="."><plain>A subcutaneous (SC) abatacept formulation is also available, allowing for administration at home, thus providing greater flexibility 22. </plain></SENT>
</text></p><p><text><SENT sid="38" pm="."><plain>The exposure–response relationship established in RA and JIA has demonstrated that abatacept steady‐state serum trough concentration (Cminss) is a good predictor of efficacy 23, 24. </plain></SENT>
<SENT sid="39" pm="."><plain>A Cminss of 10 μg/ml has been shown to correlate with near‐maximal efficacy, based on response as assessed by the Disease Activity Score in 28 joints 24 in RA and the JIA–American College of Rheumatology 30% improvement criteria (JIA‐ACR 30) 21, 23, 25 in JIA. </plain></SENT>
<SENT sid="40" pm="."><plain>In adults with RA, a weight‐tiered 10 mg/kg monthly IV dose and 125 mg weekly SC fixed dose of abatacept have shown equivalent efficacy and comparable safety 22, but the effectiveness and safety of SC abatacept in polyarticular JIA have yet to be demonstrated in a clinical trial. </plain></SENT>
</text></p><p><text><SENT sid="41" pm="."><plain>The aim of this study was to investigate the pharmacokinetics (PK), effectiveness, safety, and immunogenicity of weekly weight‐tiered treatment with SC abatacept in patients with active polyarticular JIA, including those ≥2 years of age, over a period of 24 months. </plain></SENT>
</text></p><SecTag type="METHODS"><sec id="art40466-sec-0006"><title><text><SENT sid="42" pm="."><plain>Patients and methods </plain></SENT>
</text></title><p><text><SENT sid="43" pm="."><plain>Study design. This 24‐month, single‐arm, open‐label, international, multicenter, 2‐part, phase III study 26 was initiated in August 2013 and conducted across 48 centers worldwide by members of the Paediatric Rheumatology International Trials Organisation (PRINTO) 27 and the Pediatric Rheumatology Collaborative Study Group (PRCSG) (see Appendix A for investigators who participated in this study). </plain></SENT>
<SENT sid="44" pm="."><plain>The study included 2 age cohorts (cohort 1, ages 6–17 years and cohort 2, ages 2–5 years). </plain></SENT>
<SENT sid="45" pm="."><plain>During the first 4 months (part 1), patients received open‐label SC abatacept weekly, based on body‐weight tier at each study visit (10 to &lt;25 kg [50 mg], 25 to &lt;50 kg [87.5 mg], and ≥50 kg [125 mg]) (see Supplementary Materials, available on the Arthritis &amp; Rheumatology web site at <ext-link ext-link-type="uri" xlink:href="http://onlinelibrary.wiley.com/doi/10.1002/art.40466/abstract">http://onlinelibrary.wiley.com/doi/10.1002/art.40466/abstract</ext-link> for rationale for the dosing regimen). </plain></SENT>
</text></p><p><text><SENT sid="46" pm="."><plain>At month 4, JIA‐ACR 30 responders 28 were given the opportunity to participate in a 20‐month extension (part 2 of the study) and continue open‐label abatacept treatment according to the previous dosing regimen; part 1 and part 2 formed the 24‐month cumulative period. </plain></SENT>
<SENT sid="47" pm="."><plain>Also at month 4, JIA‐ACR 30 nonresponders were given the option to continue SC abatacept for an additional 3 months and to discontinue treatment if a JIA‐ACR 30 response was not achieved by month 7. </plain></SENT>
<SENT sid="48" pm="."><plain>After part 2, long‐term follow‐up began, in which patients who completed both parts of the study entered a post‐study drug access program. </plain></SENT>
<SENT sid="49" pm="."><plain>The study was conducted in accordance with the Declaration of Helsinki 29, the International Conference on Harmonisation Guidelines for Good Clinical Practice, and local regulations. </plain></SENT>
<SENT sid="50" pm="."><plain>At each site, an institutional review board or independent ethics committee approved the protocol, consent forms, and any other written information provided to patients or their legal representatives. </plain></SENT>
</text></p><p><text><SENT sid="51" pm="."><plain>Patients. Enrolled patients met the International League of Associations for Rheumatology criteria for JIA 4 in 1 of the following categories: extended oligoarticular JIA, polyarticular JIA rheumatoid factor (RF) positive, polyarticular JIA RF negative, enthesitis‐related arthritis, psoriatic arthritis, or systemic JIA (with systemic features absent for ≥6 months prior to enrollment). </plain></SENT>
<SENT sid="52" pm="."><plain>Patients also had a history of ≥5 joints with active disease and active articular disease at baseline, defined as ≥2 active joints and ≥2 joints with limitation of motion. </plain></SENT>
</text></p><p><text><SENT sid="53" pm="."><plain>In addition, patients were naive to treatment with abatacept but may have had an inadequate response or prior intolerance to ≥1 nonbiologic or biologic DMARD, including TNFi. </plain></SENT>
<SENT sid="54" pm="."><plain>Patients with systemic JIA at onset were restricted to ≤10% of the study population, and those with a prior inadequate response to TNFi or other biologic DMARDs were restricted to ≤30% of the study population (see Supplementary Materials, available at <ext-link ext-link-type="uri" xlink:href="http://onlinelibrary.wiley.com/doi/10.1002/art.40466/abstract">http://onlinelibrary.wiley.com/doi/10.1002/art.40466/abstract</ext-link>). </plain></SENT>
<SENT sid="55" pm="."><plain>All patients or their legal representatives provided written informed consent prior to study entry. </plain></SENT>
</text></p><p><text><SENT sid="56" pm="."><plain>Study end points. The primary end point was abatacept Cminss in cohort 1 (ages 6–17 years) at month 4 of the study (end of part 1). </plain></SENT>
<SENT sid="57" pm="."><plain>Secondary end points included the proportion of patients in cohort 1 achieving JIA‐ACR 30 response by the end of part 1 and the proportion of patients with serious adverse events (SAEs), AEs, AEs leading to discontinuation, death, marked laboratory abnormalities, and positive immunogenic responses (defined as the presence of antibodies reactive with abatacept in serum) 30 in both cohorts over parts 1 and 2. </plain></SENT>
<SENT sid="58" pm="."><plain>Abatacept Cminss to month 24 (end of part 2) was an exploratory end point for both cohorts. </plain></SENT>
</text></p><p><text><SENT sid="59" pm="."><plain>Prespecified exploratory efficacy end points for both cohorts included the proportions of patients achieving JIA‐ACR 30, 50, 70, 90, 100 responses or inactive disease (modified criteria), defined as absence of active joints, physician's global assessment of disease severity ≤10 mm, and C‐reactive protein (CRP) level ≤0.6 mg/dl (based on the normal range for CRP as defined by the central analysis site) 31 over time to the end of part 2. </plain></SENT>
<SENT sid="60" pm="."><plain>JIA‐ACR response rates were not corrected for MTX or corticosteroid use; however, if patients received an intraarticular corticosteroid injection, the treated joint was designated as active for the following 3 months. </plain></SENT>
<SENT sid="61" pm="."><plain>Other prespecified exploratory end points for cohort 1 included median post‐baseline values of the 6 JIA‐ACR core set variables: number of active joints, number of joints with limitation of motion, physician's global assessment, parent's global assessment of patient overall well‐being, cross‐culturally adapted and validated version of the Childhood Health Assessment Questionnaire disability index (C‐HAQ DI) 32, and laboratory marker of acute inflammation (CRP level). </plain></SENT>
<SENT sid="62" pm="."><plain>Post hoc analyses in both cohorts were conducted to determine the median Juvenile Arthritis Disease Activity Score in 71 joints using the CRP level (JADAS‐71–CRP) 33, 34 over time, and the proportion of patients achieving low disease activity according to the JADAS‐71–CRP (cutoff value in polyarthritis ≤3.8) and remission (defined as a JADAS‐71–CRP value of ≤1 for ≥6 months) 33, 35. </plain></SENT>
<SENT sid="63" pm="."><plain>In addition, post hoc subgroup analyses of JIA‐ACR response rates and proportions of patients achieving JADAS‐71–CRP low disease activity and remission in cohort 1 were performed using baseline concomitant MTX treatment, prior biologic treatment, and JIA category as subgroups (see Supplementary Materials, available at <ext-link ext-link-type="uri" xlink:href="http://onlinelibrary.wiley.com/doi/10.1002/art.40466/abstract">http://onlinelibrary.wiley.com/doi/10.1002/art.40466/abstract</ext-link>). </plain></SENT>
</text></p><p><text><SENT sid="64" pm="."><plain>Analysis populations. In both cohorts, the PK analysis population for month 4 (end of part 1) comprised treated patients for whom PK measurements were collected in the 4–10‐day window after the most recent SC dose; these patients also had 7 consecutive weekly SC abatacept injections at the same dosage prior to month 4. </plain></SENT>
<SENT sid="65" pm="."><plain>The PK analysis population at the time points other than month 4 also comprised those patients with PK measurements collected in the 4–10‐day window after the most recent SC dose. </plain></SENT>
</text></p><p><text><SENT sid="66" pm="."><plain>Effectiveness analyses were conducted on the intent‐to‐treat (ITT) population (defined as all treated patients) for both cohorts in part 1, as prespecified. </plain></SENT>
<SENT sid="67" pm="."><plain>For part 2, an “as‐observed” analysis was planned for both cohorts. </plain></SENT>
<SENT sid="68" pm="."><plain>However, in cohort 1 (ages 6–17 years), ITT analyses were also performed for the evaluation of effectiveness (sensitivity analysis), except for median post‐baseline values for JADAS‐71–CRP and the 6 JIA‐ACR core set variables over the cumulative period. </plain></SENT>
<SENT sid="69" pm="."><plain>In cohort 2 (ages 2–5 years), only as‐observed analyses were performed for part 2, as not all patients had completed treatment at the time of database locking. </plain></SENT>
</text></p><p><text><SENT sid="70" pm="."><plain>Safety analyses were performed on the ITT population in both cohorts, taking into consideration all events during parts 1 and 2. </plain></SENT>
<SENT sid="71" pm="."><plain>Marked laboratory abnormalities criteria were prespecified (see Supplementary Materials, available at <ext-link ext-link-type="uri" xlink:href="http://onlinelibrary.wiley.com/doi/10.1002/art.40466/abstract">http://onlinelibrary.wiley.com/doi/10.1002/art.40466/abstract</ext-link>). </plain></SENT>
<SENT sid="72" pm="."><plain>Immunogenicity was assessed in patients in the ITT population for whom ≥1 post‐baseline immunogenicity result was collected. </plain></SENT>
</text></p><p><text><SENT sid="73" pm="."><plain>Statistical analysis, sample size, and power calculation. As the aim of this study was to assess the PK of SC abatacept treatment, it was not powered for statistical hypothesis testing. </plain></SENT>
<SENT sid="74" pm="."><plain>A sample size of ~160 patients for cohort 1 (ages 6–17 years) was planned to allow for assessment of PK, effectiveness, safety, and immunogenicity, resembling the sample size of the 4‐month lead‐in phase of the IV abatacept JIA study 13. </plain></SENT>
<SENT sid="75" pm="."><plain>Enrollment of ~160 patients into the 3 body‐weight tiers was predicted to ensure that the half‐width of the 90% confidence interval (90% CI) for Cminss would be within 18% of the true population mean for each body‐weight tier group, calculated based on a log‐transformed standard deviation for Cminss of 0.49. </plain></SENT>
<SENT sid="76" pm="."><plain>For JIA‐ACR 30 response, a sample of 160 patients would yield a precision of 7.4% for the half‐width of the 95% CI, assuming an underlying true responder rate of 64%, as seen with IV abatacept in JIA 13. </plain></SENT>
<SENT sid="77" pm="."><plain>For cohort 2 (ages 2–5 years), a sample size of ≥30 patients permitted initial descriptive assessment of PK, effectiveness, safety, and immunogenicity. </plain></SENT>
</text></p><p><text><SENT sid="78" pm="."><plain>All effectiveness, safety, and PK analyses were descriptive, with no formal statistical testing. </plain></SENT>
<SENT sid="79" pm="."><plain>For effectiveness analyses using the ITT population, patients with missing data were imputed as nonresponders. </plain></SENT>
<SENT sid="80" pm="."><plain>CIs for proportions were computed using normal approximation, provided that the actual number of events was ≥5; otherwise, computed CIs were calculated using an exact method. </plain></SENT>
<SENT sid="81" pm="."><plain>In order to investigate the impact of immunogenicity on effectiveness, safety, and PK, a clinical review of the data on effectiveness, safety, and PK for patients who had positive immunogenic responses was performed. </plain></SENT>
</text></p></sec></SecTag><SecTag type="RESULTS"><sec id="art40466-sec-0007"><title><text><SENT sid="82" pm="."><plain>Results </plain></SENT>
</text></title><p><text><SENT sid="83" pm="."><plain>Patient disposition and baseline characteristics. A total of 219 patients entered part 1 of the study; 173 were ages 6–17 years (cohort 1) and 46 were ages 2–5 years (cohort 2). </plain></SENT>
<SENT sid="84" pm="."><plain>As shown in Figure 1, 132 patients (76.3%) in cohort 1 and 24 (52.2%) in cohort 2 completed both parts 1 and 2. </plain></SENT>
<SENT sid="85" pm="."><plain>In both cohorts, the discontinuation rate was low across both parts of the trial; overall, the main reasons for discontinuation were lack of efficacy, withdrawal of consent, and AEs. </plain></SENT>
<SENT sid="86" pm="."><plain>Treatment in the cumulative period was ongoing for 15 patients (32.6%) in cohort 2 at the time of database locking. </plain></SENT>
<SENT sid="87" pm="."><plain>Baseline demographic and disease characteristics for cohorts 1 and 2 are shown in Table 1. </plain></SENT>
<SENT sid="88" pm="."><plain>Whereas 41.0% of patients (71 of 173) in cohort 1 had a disease duration of ≥2 years, most patients (91.3% [42 of 46]) in cohort 2—which included patients as young as 2 years of age—had a disease duration of &lt;2 years (median 0.5 years). </plain></SENT>
<SENT sid="89" pm="."><plain>At baseline, 78.6% of patients in cohort 1 and 80.4% in cohort 2 were receiving concomitant MTX. </plain></SENT>
<SENT sid="90" pm="."><plain>A protocol violation occurred in cohort 1, due to inclusion of 5 patients from noneligible JIA categories in the analysis. </plain></SENT>
<SENT sid="91" pm="."><plain>The median exposure to abatacept during the cumulative period was 24.3 months (range 1.9–28.0) in cohort 1 and 24.1 months (range 4.0–26.2) in cohort 2. </plain></SENT>
</text></p><fig fig-type="Figure" xml:lang="en" id="art40466-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p><text><SENT sid="92" pm="."><plain>Patient disposition. * = treatment ongoing at time of analysis in 15 patients (32.6%). AEs = adverse events. </plain></SENT>
</text></p></caption><graphic id="nlm-graphic-1" xlink:href="ART-70-1144-g001"/></fig><SecTag type="TABLE"></SecTag><p><text><SENT sid="308" pm="."><plain>Local injection site reactions were of mild or moderate intensity and occurred in 12 patients (6.9%) in cohort 1 and 2 (4.3%) in cohort 2 (none of which led to discontinuation). </plain></SENT>
<SENT sid="309" pm="."><plain>Seven local injection site reactions of moderate intensity occurred in 3 patients in cohort 1, and 1 patient required treatment. </plain></SENT>
<SENT sid="310" pm="."><plain>The overall rates of patients with infections in cohorts 1 and 2, respectively, were 68.2% and 78.3%. </plain></SENT>
<SENT sid="311" pm="."><plain>All marked laboratory abnormalities were mild or moderate, and no deaths occurred during the study (for further details, see Supplementary Materials, available on the Arthritis &amp; Rheumatology web site at <ext-link ext-link-type="uri" xlink:href="http://onlinelibrary.wiley.com/doi/10.1002/art.40466/abstract">http://onlinelibrary.wiley.com/doi/10.1002/art.40466/abstract</ext-link>). </plain></SENT>
</text></p><p><text><SENT sid="312" pm="."><plain>Overall, 4 of 172 patients (2.3%) in cohort 1, and 4 of 46 (8.7%) in cohort 2 developed antibodies reactive with abatacept while receiving treatment during the cumulative period, but antibody positivity did not persist. </plain></SENT>
<SENT sid="313" pm="."><plain>The presence of these antibodies had no apparent effect on PK, effectiveness, or safety (see Supplementary Materials, available at <ext-link ext-link-type="uri" xlink:href="http://onlinelibrary.wiley.com/doi/10.1002/art.40466/abstract">http://onlinelibrary.wiley.com/doi/10.1002/art.40466/abstract</ext-link>). </plain></SENT>
</text></p></sec></SecTag><SecTag type="DISCUSS"><sec id="art40466-sec-0008"><title><text><SENT sid="314" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="315" pm="."><plain>In this phase III study of weekly weight‐tiered SC abatacept in patients with polyarticular JIA, the primary end point of abatacept Cminss at month 4 in patients ages 6–17 years was shown to be consistently above the planned minimal target therapeutic exposure of Cminss 10 μg/ml, without compromising patient safety. </plain></SENT>
<SENT sid="316" pm="."><plain>The target therapeutic exposure was achieved at month 4 across all weight groups in cohort 1, and overall in cohort 2. </plain></SENT>
<SENT sid="317" pm="."><plain>SC abatacept was effective and improved function and patient well‐being over the 24‐month cumulative treatment period in both cohorts, with a low rate of discontinuation due to AEs. </plain></SENT>
</text></p><p><text><SENT sid="318" pm="."><plain>The PK data confirm the feasibility of a weekly weight‐tiered SC abatacept treatment regimen for polyarticular JIA in patients ages 2–17 years old (see Supplementary Materials, <ext-link ext-link-type="uri" xlink:href="http://onlinelibrary.wiley.com/doi/10.1002/art.40466/abstract">http://onlinelibrary.wiley.com/doi/10.1002/art.40466/abstract</ext-link>). </plain></SENT>
<SENT sid="319" pm="."><plain>The observed Cminss values were within the ranges of exposure previously found for IV abatacept (10 mg/kg) in patients with JIA 23 and in adults with RA receiving IV or SC abatacept treatment 36 (also see Supplementary Materials). </plain></SENT>
<SENT sid="320" pm="."><plain>Abatacept Cminss values at months 4 and 24 were comparable, demonstrating that the target therapeutic exposure is maintained with continued treatment. </plain></SENT>
</text></p><p><text><SENT sid="321" pm="."><plain>The robust JIA‐ACR response rates and improvements in JADAS‐71–CRP scores to month 24 demonstrated in our study support the use of weekly weight‐tiered SC abatacept therapy in patients with polyarticular JIA. </plain></SENT>
<SENT sid="322" pm="."><plain>In both cohorts, an early onset of treatment response was observed, with responses maintained throughout the study. </plain></SENT>
<SENT sid="323" pm="."><plain>In cohort 1, analysis of the 6 JIA‐ACR core variables revealed a beneficial effect of SC abatacept on function (C‐HAQ DI) and well‐being (parent's global assessment of patient overall well‐being). </plain></SENT>
</text></p><p><text><SENT sid="324" pm="."><plain>SC abatacept was well tolerated in both cohorts, with no new safety concerns observed. </plain></SENT>
<SENT sid="325" pm="."><plain>Safety and immunogenicity profiles were similar in cohorts 1 and 2. </plain></SENT>
<SENT sid="326" pm="."><plain>Although the rate of infections was higher than that observed in a study of adult patients with RA who were treated with abatacept 16, this finding was somewhat expected due to a known greater susceptibility of children to infections as compared with adults. </plain></SENT>
<SENT sid="327" pm="."><plain>Notably, there were no reported opportunistic infections related to abatacept treatment in patients with polyarticular JIA, even in countries with a high burden of tuberculosis, which is consistent with observations in adults with RA who receive abatacept treatment 37. </plain></SENT>
<SENT sid="328" pm="."><plain>In addition, there were no malignancies or autoimmune disorders in cohort 2, and the rate of these events was minimal in cohort 1. </plain></SENT>
<SENT sid="329" pm="."><plain>The safety of SC abatacept was largely consistent with that of IV abatacept in polyarticular JIA 2, 9, 13. </plain></SENT>
</text></p><p><text><SENT sid="330" pm="."><plain>Tolerability of SC injections is of special concern in pediatric patients. </plain></SENT>
<SENT sid="331" pm="."><plain>In this study, SC abatacept treatment yielded an overall low rate of local injection site reactions, most of which were mild—only a few moderate and no severe reactions were reported. </plain></SENT>
<SENT sid="332" pm="."><plain>Notably, no local injection site reactions led to treatment discontinuation. </plain></SENT>
<SENT sid="333" pm="."><plain>Fewer patients developed anti‐abatacept antibodies while receiving SC abatacept treatment compared with IV abatacept treatment 2; this was somewhat expected given that similar trends were observed in a study of adult patients with RA who received SC or IV abatacept plus MTX and had inadequate responses to MTX 22. </plain></SENT>
<SENT sid="334" pm="."><plain>This finding was also possibly related to the concomitant use of MTX in ≥75% of patients in the current study and differences in study designs. </plain></SENT>
</text></p><p><text><SENT sid="335" pm="."><plain>The effectiveness of SC abatacept treatment demonstrated in the current study constitutes a conservative interpretation of the data. </plain></SENT>
<SENT sid="336" pm="."><plain>Despite the observational character of the study, an ITT analysis was performed for the cumulative period in cohort 1 and up to month 4 in cohort 2, in which patients discontinuing the study prior to month 24 or not having data available at this time point were imputed as nonresponders. </plain></SENT>
</text></p><p><text><SENT sid="337" pm="."><plain>Abatacept is seldom used to treat polyarticular JIA early in the disease course. </plain></SENT>
<SENT sid="338" pm="."><plain>The results from cohort 2 in this study, in which abatacept treatment was initiated in patients with a median disease duration of only 0.5 years, provide valuable data regarding the early introduction of abatacept therapy; notably, JIA‐ACR response rates were consistently higher in cohort 2 than in cohort 1. </plain></SENT>
</text></p><p><text><SENT sid="339" pm="."><plain>The study has some limitations, including the open‐label design and a protocol violation, in which a few patients with undifferentiated and persistent oligoarthritis entered the trial despite not meeting the eligibility criteria. </plain></SENT>
<SENT sid="340" pm="."><plain>Additionally, the use of concomitant medications such as MTX and corticosteroids, as well as prior use of biologic DMARDs (including TNFi) in some patients, may have had confounding effects. </plain></SENT>
<SENT sid="341" pm="."><plain>However, the sample sizes of the corresponding subgroups were too small to analyze. </plain></SENT>
</text></p><p><text><SENT sid="342" pm="."><plain>In conclusion, weight‐tiered weekly SC abatacept was effective in patients with polyarticular JIA, with no new safety concerns identified. </plain></SENT>
<SENT sid="343" pm="."><plain>These data suggest that SC abatacept provides an effective and well‐tolerated treatment option for patients with polyarticular JIA, with the additional benefit of the convenience associated with self or parent/caregiver administration of the treatment. </plain></SENT>
</text></p></sec></SecTag><SecTag type="AUTH_CONT"><sec id="art40466-sec-0010"><title><text><SENT sid="344" pm="."><plain>Author contributions </plain></SENT>
</text></title><p><text><SENT sid="345" pm="."><plain>All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be published. </plain></SENT>
</text></p><p><text><SENT sid="346" pm="."><plain>Dr. Brunner had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. </plain></SENT>
</text></p><sec id="art40466-sec-0011"><title><text><SENT sid="347" pm="."><plain>Study conception and design </plain></SENT>
</text></title><p><text><SENT sid="348" pm="."><plain>Brunner, Lovell, Martini, Ruperto, Wong. </plain></SENT>
</text></p></sec><sec id="art40466-sec-0012"><title><text><SENT sid="349" pm="."><plain>Acquisition of data </plain></SENT>
</text></title><p><text><SENT sid="350" pm="."><plain>Brunner, Tzaribachev, Vega‐Cornejo, Louw, Berman, Calvo Penadés, Antón, Ávila‐Zapata, Cuttica, Horneff, Foeldvari, Keltsev, Kingsbury, Viola, Joos, Lauwerys, Paz Gastañaga, Rama, Wouters, Bohnsack, Breedt, Fischbach, Lutz, Minden, Miraval, Ally, Rubio‐Pérez, Solau Gervais, van Zyl, Lovell, Ruperto. </plain></SENT>
</text></p></sec><sec id="art40466-sec-0013"><title><text><SENT sid="351" pm="."><plain>Analysis and interpretation of data </plain></SENT>
</text></title><p><text><SENT sid="352" pm="."><plain>Brunner, Tzaribachev, Vega‐Cornejo, Louw, Berman, Calvo Penadés, Antón, Ávila‐Zapata, Cuttica, Horneff, Foeldvari, Keltsev, Kingsbury, Viola, Joos, Lauwerys, Paz Gastañaga, Rama, Wouters, Bohnsack, Breedt, Fischbach, Lutz, Minden, Miraval, Ally, Rubio‐Pérez, Solau Gervais, van Zyl, Li, Nys, Wong, Banerjee, Lovell, Martini, Ruperto. </plain></SENT>
</text></p></sec></sec></SecTag><sec id="art40466-sec-0014"><title><text><SENT sid="353" pm="."><plain>Role of the study sponsor </plain></SENT>
</text></title><p><text><SENT sid="354" pm="."><plain>The study was designed jointly by academic authors and Bristol‐Myers Squibb, with data collected by PRINTO/PRCSG investigators. </plain></SENT>
<SENT sid="355" pm="."><plain>The first and subsequent versions of the manuscript were written, edited, and revised critically by academic authors. </plain></SENT>
<SENT sid="356" pm="."><plain>Bristol‐Myers Squibb facilitated the study design and reviewed and approved the manuscript prior to submission. </plain></SENT>
<SENT sid="357" pm="."><plain>All authors independently collected the data, interpreted the results, had the final decision to submit the manuscript for publication, and had the right to accept or reject comments or suggestions. </plain></SENT>
<SENT sid="358" pm="."><plain>Writing assistance was funded by Bristol‐Myers Squibb. </plain></SENT>
<SENT sid="359" pm="."><plain>Publication of this article was not contingent upon approval by Bristol‐Myers Squibb. </plain></SENT>
</text></p></sec><SecTag type="SUPPL"><sec sec-type="supplementary-material"><title><text><SENT sid="360" pm="."><plain>Supporting information </plain></SENT>
</text></title><supplementary-material content-type="local-data" id="art40466-sup-0001"><caption><p><text><SENT sid="361" pm="."><plain>  </plain></SENT>
</text></p></caption><media xlink:href="ART-70-1144-s001.docx"><caption><p><text><SENT sid="362" pm="."><plain>Click here for additional data file. </plain></SENT>
</text></p></caption></media></supplementary-material></sec></SecTag></body><back><SecTag type="ACK_FUND"><ack id="art40466-sec-0009"><title>Acknowledgments</title><p><text4fund><text><SENT sid="363" pm="."><plain>The authors would like to thank Marco Garrone, PRINTO, for editorial assistance. </plain></SENT>
<SENT sid="364" pm="."><plain>Professional medical writing and editorial assistance was provided by Katerina Kumpan, PhD, at Caudex, and was funded by Bristol‐Myers Squibb. </plain></SENT>
<SENT sid="365" pm="."><plain>The authors are grateful to the protocol manager of this study, Mary Swingle, Bristol‐Myers Squibb. </plain></SENT>
</text></text4fund></p></ack></SecTag><SecTag type="REF"><ref-list content-type="cited-references" id="art40466-bibl-0001"><title>References</title><ref id="art40466-bib-0001"><text><SENT sid="366" pm="."><plain>1  Ravelli A ,  Martini A . Juvenile idiopathic arthritis. Lancet 2007;369:767–78.17336654 </plain></SENT>
</text></ref><ref id="art40466-bib-0002"><text><SENT sid="367" pm="."><plain>2  Ruperto N ,  Lovell DJ ,  Quartier P ,  Paz E ,  Rubio‐Pérez N ,  Silva CA , et al. Long‐term safety and efficacy of abatacept in children with juvenile idiopathic arthritis. Arthritis Rheum 2010;62:1792–802.20191582 </plain></SENT>
</text></ref><ref id="art40466-bib-0003"><text><SENT sid="368" pm="."><plain>3  Webb K ,  Wedderburn LR . Advances in the treatment of polyarticular juvenile idiopathic arthritis. Curr Opin Rheumatol 2015;27:505–10.26147756 </plain></SENT>
</text></ref><ref id="art40466-bib-0004"><text><SENT sid="369" pm="."><plain>4  Petty RE ,  Southwood TR ,  Manners P ,  Baum J ,  Glass DN ,  Goldenberg J , et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390–2.14760812 </plain></SENT>
</text></ref><ref id="art40466-bib-0005"><text><SENT sid="370" pm="."><plain>5  Rosenberg AM ,  Oen KG . Polyarticular juvenile idiopathic arthritis In: PettyRE, LaxerRM, LindsleyCB, WedderburnLR, editors. Textbook of pediatric rheumatology. 7th ed Philadelphia: Elsevier Health Sciences; 2015 p. 217. </plain></SENT>
</text></ref><ref id="art40466-bib-0006"><text><SENT sid="371" pm="."><plain>6  Beukelman T ,  Patkar NM ,  Saag KG ,  Tolleson‐Rinehart S ,  Cron RQ ,  DeWitt EM , et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken) 2011;63:465–82.21452260 </plain></SENT>
</text></ref><ref id="art40466-bib-0007"><text><SENT sid="372" pm="."><plain>7  Brunner HI ,  Ruperto N ,  Zuber Z ,  Keane C ,  Harari O ,  Kenwright A , et al. Efficacy and safety of tocilizumab in patients with polyarticular‐course juvenile idiopathic arthritis: results from a phase 3, randomised, double‐blind withdrawal trial. Ann Rheum Dis 2015;74:1110–7.24834925 </plain></SENT>
</text></ref><ref id="art40466-bib-0008"><text><SENT sid="373" pm="."><plain>8  Brunner HI ,  Ruperto N ,  Tzaribachev N ,  Horneff G ,  Chasnyk VG ,  Panaviene V , et al. Subcutaneous golimumab for children with active polyarticular‐course juvenile idiopathic arthritis: results of a multicentre, double‐blind, randomised‐withdrawal trial. Ann Rheum Dis 2018;77:21–9.28507219 </plain></SENT>
</text></ref><ref id="art40466-bib-0009"><text><SENT sid="374" pm="."><plain>9  Lovell D ,  Ruperto N ,  Mouy R ,  Paz E ,  Rubio‐Pérez N ,  Silva CA , et al. Long‐term safety, efficacy, and quality of life in patients with juvenile idiopathic arthritis treated with intravenous abatacept for up to seven years. Arthritis Rheumatol 2015;67:2759–70.26097215 </plain></SENT>
</text></ref><ref id="art40466-bib-0010"><text><SENT sid="375" pm="."><plain>10  Lovell DJ ,  Giannini EH ,  Reiff A ,  Cawkwell GD ,  Silverman ED ,  Nocton JJ , et al, for the Pediatric Rheumatology Collaborative Study Group . Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000;342:763–9.10717011 </plain></SENT>
</text></ref><ref id="art40466-bib-0011"><text><SENT sid="376" pm="."><plain>11  Lovell DJ ,  Ruperto N ,  Goodman S ,  Reiff A ,  Jung L ,  Jarosova K , et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008;359:810–20.18716298 </plain></SENT>
</text></ref><ref id="art40466-bib-0012"><text><SENT sid="377" pm="."><plain>12  Ruperto N ,  Lovell DJ ,  Cuttica R ,  Wilkinson N ,  Woo P ,  Espada G , et al. A randomized, placebo‐controlled trial of infliximab plus methotrexate for the treatment of polyarticular‐course juvenile rheumatoid arthritis. Arthritis Rheum 2007;56:3096–106.17763439 </plain></SENT>
</text></ref><ref id="art40466-bib-0013"><text><SENT sid="378" pm="."><plain>13  Ruperto N ,  Lovell DJ ,  Quartier P ,  Paz E ,  Rubio‐Perez N ,  Silva CA , et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double‐blind, placebo‐controlled withdrawal trial. Lancet 2008;372:383–91.18632147 </plain></SENT>
</text></ref><ref id="art40466-bib-0014"><text><SENT sid="379" pm="."><plain>14  Silverman E ,  Spiegel L ,  Hawkins D ,  Petty R ,  Goldsmith D ,  Schanberg L , et al. Long‐term open‐label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular‐course juvenile rheumatoid arthritis. Arthritis Rheum 2005;52:554–62.15693001 </plain></SENT>
</text></ref><ref id="art40466-bib-0015"><text><SENT sid="380" pm="."><plain>15  Silverman E ,  Mouy R ,  Spiegel L ,  Jung LK ,  Saurenmann RK ,  Lahdenne P , et al. Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med 2005;352:1655–66.15843668 </plain></SENT>
</text></ref><ref id="art40466-bib-0016"><text><SENT sid="381" pm="."><plain>16  Genovese MC ,  Schiff M ,  Luggen M ,  Becker JC ,  Aranda R ,  Teng J , et al. Efficacy and safety of the selective co‐stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti‐tumour necrosis factor therapy. Ann Rheum Dis 2008;67:547–54.17921185 </plain></SENT>
</text></ref><ref id="art40466-bib-0017"><text><SENT sid="382" pm="."><plain>17 Orencia (abatacept) prescribing information. Princeton (NJ): Bristol‐Myers Squibb; 2017 URL: <ext-link ext-link-type="uri" xlink:href="http://packageinserts.bms.com/pi/pi_orencia.pdf">http://packageinserts.bms.com/pi/pi_orencia.pdf</ext-link>. </plain></SENT>
</text></ref><ref id="art40466-bib-0018"><text><SENT sid="383" pm="."><plain>18  Mease PJ ,  Gottlieb AB ,  van der Heijde D ,  FitzGerald O ,  Johnsen A ,  Nys M , et al. Efficacy and safety of abatacept, a T‐cell modulator, in a randomised, double‐blind, placebo‐controlled, phase III study in psoriatic arthritis. Ann Rheum Dis 2017;76:1550–8.28473423 </plain></SENT>
</text></ref><ref id="art40466-bib-0019"><text><SENT sid="384" pm="."><plain>19  Kremer JM ,  Genant HK ,  Moreland LW ,  Russell AS ,  Emery P ,  Abud‐Mendoza C , et al. Results of a two‐year follow up study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum 2008;58:953–63.18383390 </plain></SENT>
</text></ref><ref id="art40466-bib-0020"><text><SENT sid="385" pm="."><plain>20  Westhovens R ,  Kremer JM ,  Moreland LW ,  Emery P ,  Russell AS ,  Li T , et al. Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5‐year extended phase IIB study. J Rheumatol 2009;36:736–42.19273451 </plain></SENT>
</text></ref><ref id="art40466-bib-0021"><text><SENT sid="386" pm="."><plain>21  Lovell D ,  Ruperto N ,  Tzaribachev N ,  Zeft A ,  Cimaz R ,  Stanevica V , et al. Long‐term effectiveness and safety of abatacept in juvenile idiopathic arthritis: interim results from the abatacept in JIA registry [abstract]. Arthritis Rheumatol 2016;68 Suppl 10 URL: <ext-link ext-link-type="uri" xlink:href="http://acrabstracts.org/abstract/long-term-effectiveness-and-safety-of-abatacept-in-juvenile-idiopathic-arthritis-interim-results-from-the-abatacept-in-jia-registry-2/">http://acrabstracts.org/abstract/long-term-effectiveness-and-safety-of-abatacept-in-juvenile-idiopathic-arthritis-interim-results-from-the-abatacept-in-jia-registry-2/</ext-link>. </plain></SENT>
</text></ref><ref id="art40466-bib-0022"><text><SENT sid="387" pm="."><plain>22  Genovese MC ,  Covarrubias A ,  Leon G ,  Mysler E ,  Keiserman M ,  Valente R , et al. Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum 2011;63:2854–64.21618201 </plain></SENT>
</text></ref><ref id="art40466-bib-0023"><text><SENT sid="388" pm="."><plain>23  Li X ,  Passarell JA ,  Lin K ,  Roy A ,  Murthy B ,  Girgis IG . Population pharmacokinetics and exposure‐response analyses for abatacept in juvenile idiopathic arthritis [poster]. </plain></SENT>
<SENT sid="389" pm="."><plain>Presented at the American Conference on Pharmacometrics (ACoP8); 2017 October 15–18; Fort Lauderdale, FL. </plain></SENT>
</text></ref><ref id="art40466-bib-0024"><text><SENT sid="390" pm="."><plain>24  Zhou Z ,  Roy A ,  Murthy B ,  Gao L ,  Teng J ,  Kaul S , et al. Relationship between systemic exposure and the efficacy and safety of abatacept administered subcutaneously and intravenously in adult rheumatoid arthritis patients [poster]. </plain></SENT>
<SENT sid="391" pm="."><plain>Presented at the American Association of Pharmaceutical Scientists National Biotechnology Conference; 2011 May 16–18; San Francisco, CA. </plain></SENT>
</text></ref><ref id="art40466-bib-0025"><text><SENT sid="392" pm="."><plain>25  Ruperto N ,  Lovell DJ ,  Tzaribachez N ,  Vega‐Cornejo G ,  Louw I ,  Berman A , et al. Subcutaneous abatacept in patients with polyarticular juvenile idiopathic arthritis and inadequate response to biologic or non‐biologic disease‐modifying antirheumatic drugs: pharmacokinetics, efficacy and safety. Ann Rheum Dis 2016;75:138. </plain></SENT>
</text></ref><ref id="art40466-bib-0026"><text><SENT sid="393" pm="."><plain>26 Bristol‐Myers Squibb, sponsor . A phase 3 multi‐center, open‐label study to evaluate pharmacokinetics, efficacy and safety of abatacept administered subcutaneously (SC) in children and adolescents with active polyarticular juvenile idiopathic arthritis (pJIA) and inadequate response (IR) to biologic or non biologic disease modifying anti‐rheumatic drugs (DMARDs). </plain></SENT>
<SENT sid="394" pm="."><plain>ClinicalTrials.gov identifier: NCT01844518; 2013. </plain></SENT>
</text></ref><ref id="art40466-bib-0027"><text><SENT sid="395" pm="."><plain>27  Ruperto N ,  Martini A . Networking in paediatrics: the example of the Paediatric Rheumatology International Trials Organisation (PRINTO). Arch Dis Child 2011;96:596–601.21317432 </plain></SENT>
</text></ref><ref id="art40466-bib-0028"><text><SENT sid="396" pm="."><plain>28  Giannini EH ,  Ruperto N ,  Ravelli A ,  Lovell DJ ,  Felson DT ,  Martini A . Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202–9.9214419 </plain></SENT>
</text></ref><ref id="art40466-bib-0029"><text><SENT sid="397" pm="."><plain>29 World Medical Association Declaration of Helsinki (1964) . Recommendations guiding physicians in biomedical research involving human subjects. BMJ 1996;313:1448. </plain></SENT>
</text></ref><ref id="art40466-bib-0030"><text><SENT sid="398" pm="."><plain>30  Haggerty HG ,  Abbott MA ,  Reilly TP ,  DeVona DA ,  Gleason CR ,  Tay L , et al. Evaluation of immunogenicity of the T cell costimulation modulator abatacept in patients treated for rheumatoid arthritis. J Rheumatol 2007;34:2365–73.18050376 </plain></SENT>
</text></ref><ref id="art40466-bib-0031"><text><SENT sid="399" pm="."><plain>31  Wallace CA ,  Giannini EH ,  Huang B ,  Itert L ,  Ruperto N , for the Childhood Arthritis and Rheumatology Research Alliance (CARRA), the Pediatric Rheumatology Collaborative Study Group (PRCSG), and the Paediatric Rheumatology International Trials Organisation (PRINTO) . American College of Rheumatology provisional criteria for defining clinical inactive disease in select categories of juvenile idiopathic arthritis. Arthritis Care Res (Hoboken) 2011;63:929–36.21717596 </plain></SENT>
</text></ref><ref id="art40466-bib-0032"><text><SENT sid="400" pm="."><plain>32  Ruperto N ,  Ravelli A ,  Pistorio A ,  Malattia C ,  Cavuto S ,  Gado‐West L , et al. Cross‐cultural adaptation and psychometric evaluation of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 32 countries: review of the general methodology. Clin Exp Rheumatol 2001;19:S1–S9. </plain></SENT>
</text></ref><ref id="art40466-bib-0033"><text><SENT sid="401" pm="."><plain>33  Nordal EB ,  Zak M ,  Aalto K ,  Berntson L ,  Fasth A ,  Herlin T , et al. Validity and predictive ability of the juvenile arthritis disease activity score based on CRP versus ESR in a Nordic population‐based setting. Ann Rheum Dis 2012;71:1122–7.22258487 </plain></SENT>
</text></ref><ref id="art40466-bib-0034"><text><SENT sid="402" pm="."><plain>34  Consolaro A ,  Ruperto N ,  Bazso A ,  Pistorio A ,  Magni‐Manzoni S ,  Filocamo G , et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum 2009;61:658–66.19405003 </plain></SENT>
</text></ref><ref id="art40466-bib-0035"><text><SENT sid="403" pm="."><plain>35  Consolaro A ,  Bracciolini G ,  Ruperto N ,  Pistorio A ,  Magni‐Manzoni S ,  Malattia C , et al. Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: defining criteria based on the juvenile arthritis disease activity score. Arthritis Rheum 2012;64:2366–74.22231288 </plain></SENT>
</text></ref><ref id="art40466-bib-0036"><text><SENT sid="404" pm="."><plain>36  Iwahashi M ,  Inoue H ,  Matsubara T ,  Tanaka T ,  Amano K ,  Kanamono T , et al. Efficacy, safety, pharmacokinetics, and immunogenicity of abatacept administered subcutaneously or intravenously in Japanese patients with rheumatoid arthritis and inadequate response to methotrexate: a Phase II/III, randomized study. Mod Rheumatol 2014;24:885–91.24708204 </plain></SENT>
</text></ref><ref id="art40466-bib-0037"><text><SENT sid="405" pm="."><plain>37  Louw I ,  Ally M ,  Janse van Rensburg DC ,  van Duuren E ,  Nel D ,  Miller‐Janson H , et al. Retention of use and safety of subcutaneous abatacept in rheumatoid arthritis: a patient record assessment in a compassionate use programme in South Africa, a tuberculosis endemic country [abstract]. Arthritis Rheumatol 2016;68 Suppl 10 URL: <ext-link ext-link-type="uri" xlink:href="http://acrabstracts.org/abstract/retention-of-use-and-safety-of-subcutaneous-abatacept-in-rheumatoid-arthritis-a-patient-record-assessment-in-a-compassionate-use-programme-in-south-africa-a-tuberculosis-endemic-country/">http://acrabstracts.org/abstract/retention-of-use-and-safety-of-subcutaneous-abatacept-in-rheumatoid-arthritis-a-patient-record-assessment-in-a-compassionate-use-programme-in-south-africa-a-tuberculosis-endemic-country/</ext-link>. </plain></SENT>
</text></ref></ref-list></SecTag><SecTag type="APPENDIX"><app-group><app id="art40466-app-0001" content-type="Appendix"><label>Appendix A</label><title>Study investigators</title><sec id="art40466-sec-0015"><p>The following investigators participated in the study: Mara L Becker (The Children's Mercy Hospital and Clinics, Kansas City, MO), Norman T Ilowite (Montefiore Medical Center, Bronx, NY), Jason A Dare (Arkansas Children's Hospital, Little Rock), Paula K Morris (Arkansas Children's Hospital, Little Rock), Timothy G Beukelman (The Children's Hospital of Alabama, Birmingham), Linda Wagner‐Weiner (The University of Chicago, Chicago, Illinois), Lawrence Zemel (Connecticut Children's Medical Center, Hartford), Pierre Quartier (Groupe Hospitalier Necker‐Enfants Malades, Paris, France), Isabelle Kone‐Paut (CHU de Bicêtre Service de pédiatrie, Kremlin‐Bicêtre Cedex, France), Alexandre Belot (Hôpital Femme Mère Enfant, Lyon, France), Valeria Gerloni (Istituto Ortopedico Gaetano Pini, Milan, Italy), Manuel Ferrandiz (Instituto Nacional de Salúd del Niño, Breña, Peru), Dina Janse Van Rensburg (Emmed Research, Eloffsdal, South Africa), Iloite Maria Scheibel (Hospital Nossa Senhora De Conceição, Porto Alegre, Brazil), Claudia Goldstein‐Schainberg (Hospital das Clínicas da Faculdade de Medicina da USP, São Paulo, Brazil), Clovis Silva (Hospital das Clínicas da Faculdade de Medicina da USP, São Paulo, Brazil), Maria Teresa Sande e Lemos Ascensao Terreri (UNIFESP‐Universidade Federal de São Paulo, São Paulo, Brazil), Maria Gamir (Hospital Universitario Ramón y Cajal, Madrid, Spain), Ruben Burgos Vargas (Hospital General de México, Mexico City, Mexico), Enrique Faugier Fuentes (Hospital Infantil de México Federico Gómez, Mexico City, Mexico), Rolando Cimaz (Ospedale Pediatrico Anna Meyer, Florence, Italy), Maria Alessio (Università degli Studi di Napoli Federico II, Naples, Italy) and Graciela Espada (Hospital de Niños Dr Ricardo Gutiérrez, Buenos Aires, Argentina).</p></sec></app></app-group></SecTag></back></article>
